REVIEW OF CURRENT AND EMERGING ANTIFIBROTIC THERAPY FOR ASBESTOSIS AND SILICOSIS
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Sprache: | Englisch |
| Veröffentlicht: |
Zenodo
2026
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901608164491264 |
|---|---|
| author | Sheeba S.1, Julliyan Dilleban A.1*, Venkateshan N.2, Naveena B.1, Filander Kartsan S.1, Abinaya S. P.1 |
| author_facet | Sheeba S.1, Julliyan Dilleban A.1*, Venkateshan N.2, Naveena B.1, Filander Kartsan S.1, Abinaya S. P.1 |
| contents | <p class="MsoNormal"><span>Asbestosis and silicosis are progressive occupational lung diseases driven by asbestos fiber and respirable crystalline silica inhalation, resulting in chronic inflammation and irreversible pulmonary fibrosis. While prevention and early diagnosis remain paramount due to the lack of curative options, current supportive therapies offer limited efficacy. This review examines their pathogenesis, immune mechanisms, and management strategies, with emphasis on antifibrotic agents like pirfenidone and nintedanib, alongside emerging therapies such as PDE4B inhibitors (e.g., nerandomilast) and stem cell approaches. Recent clinical data suggest slowed fibrosis progression, but occupational-specific RCTs are needed to optimize safety, efficacy, and biomarkers in high-risk cohorts like construction workers.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19884494 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | REVIEW OF CURRENT AND EMERGING ANTIFIBROTIC THERAPY FOR ASBESTOSIS AND SILICOSIS Sheeba S.1, Julliyan Dilleban A.1*, Venkateshan N.2, Naveena B.1, Filander Kartsan S.1, Abinaya S. P.1 <p class="MsoNormal"><span>Asbestosis and silicosis are progressive occupational lung diseases driven by asbestos fiber and respirable crystalline silica inhalation, resulting in chronic inflammation and irreversible pulmonary fibrosis. While prevention and early diagnosis remain paramount due to the lack of curative options, current supportive therapies offer limited efficacy. This review examines their pathogenesis, immune mechanisms, and management strategies, with emphasis on antifibrotic agents like pirfenidone and nintedanib, alongside emerging therapies such as PDE4B inhibitors (e.g., nerandomilast) and stem cell approaches. Recent clinical data suggest slowed fibrosis progression, but occupational-specific RCTs are needed to optimize safety, efficacy, and biomarkers in high-risk cohorts like construction workers.</span></p> |
| title | REVIEW OF CURRENT AND EMERGING ANTIFIBROTIC THERAPY FOR ASBESTOSIS AND SILICOSIS |
| url | https://doi.org/10.5281/zenodo.19884494 |